Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Frost & Sullivan
DP3 enables real-time remote expert diagnosis, enabling pathologists to manage workflows comprehensively and time-efficiently
MOUNTAIN VIEW, Calif., June 4, 2014 /PRNewswire/ -- Based on its recent analysis of the image-centric workflow platforms market, Frost & Sullivan recognizes Corista with the 2014 North America Frost & Sullivan Award for New Product Innovation. Corista's DP3 platform significantly improves image management for digital pathology by being a unified system, connecting scanners of all makes and models to pathologists within an organization and across the world.
Using the hardware-agnostic DP3, a pathologist or a physician can access slide images and offer diagnosis from any location on any browser-enabled device, including mobile tablets. This platform enables smaller, remote facilities to have their digital images read by external experts, regardless of location or the scanner they are using.
"DP3 not only offers browser-based access from any connected device, but also aids the gathering and search of structured data through its customer-configurable synoptic reporting," said Frost & Sullivan Senior Industry Analyst Divyaa Ravishankar. "Its image-centric approach is also user-centric, with clean, intuitive interfaces that improve its ease of use and adoptability. DP3's synchronized viewing and collaboration capabilities allow pathologists to collaborate on cases in both real-time, or within their regular workflows."
Additionally, the platform's integrated support for use in tumor boards brings diagnostic imaging to the forefront in support of cross-department decision-making and peer review. Hospitals can achieve a substantial improvement in their pathological workflow and, eventually, better patient outcomes because of its ability to significantly improve image management for digital pathology and telepathology.
Each year, Frost & Sullivan presents this award to the company that has developed an innovative product element by leveraging leading-edge technologies. Its value-added features increase customer acquisition and market penetration.
Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.
Headquartered in Concord, MA, Corista was founded in 2005. Corista's mission is to provide pathologists a workflow environment allowing them to reach and support more patients and their physicians. Corista's goal is to provide the technology that delivers the right patient with the right case to the right pathologist at the right time.
Corista's Digital Pathology Network Platform (DP3) is the only image-centric pathology workflow solution integrating multiple facilities, scanners, physicians, patients and LISs in the extended healthcare enterprise.
Corista empowers pathologist to get it right, faster - regardless of location.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion.
©2012 PR Newswire. All Rights Reserved.